Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 1/2023

Inhalt (22 Artikel)

Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma

  • Open Access
  • Original Article

Lucia Longhitano, Nunzio Vicario, Stefano Forte, Cesarina Giallongo, Giuseppe Broggi, Rosario Caltabiano, Giuseppe Maria Vincenzo Barbagallo, Roberto Altieri, Giuseppina Raciti, Michelino Di Rosa, Massimo Caruso, Rosalba Parenti, Arcangelo Liso, Federica Busi, Marco Lolicato, Maria Caterina Mione, Giovanni Li Volti, Daniele Tibullo

Correction to: Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma

  • Open Access
  • Correction

Lucia Longhitano, Nunzio Vicario, Stefano Forte, Cesarina Giallongo, Giuseppe Broggi, Rosario Caltabiano, Giuseppe Maria Vincenzo Barbagallo, Roberto Altieri, Giuseppina Raciti, Michelino Di Rosa, Massimo Caruso, Rosalba Parenti, Arcangelo Liso, Federica Busi, Marco Lolicato, Maria Caterina Mione, Giovanni Li Volti, Daniele Tibullo

Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors

  • Open Access
  • Original Article

Chen Wei, Mengyu Wang, Quanli Gao, Shasha Yuan, Wenying Deng, Liangyu Bie, Yijie Ma, Chi Zhang, Shuyi Li, Suxia Luo, Ning Li

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

  • Open Access
  • Original Article

Natsuki Nakagawa, Yoshiko Hashii, Hisako Kayama, Ryu Okumura, Hiroko Nakajima, Hikaru Minagawa, Soyoko Morimoto, Fumihiro Fujiki, Jun Nakata, Toshiro Shirakawa, Takane Katayama, Kiyoshi Takeda, Akihiro Tsuboi, Keiichi Ozono

Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients

  • Open Access
  • Original Article

Maria Davern, Noel E. Donlon, Fiona O’Connell, Caoimhe Gaughan, Cillian O’Donovan, Mohammed Habash, Andrew D. Sheppard, Michael MacLean, Margaret R. Dunne, Jenny Moore, Hugo Temperley, Melissa J. Conroy, Christine Butler, Anshul Bhardwaj, Narayanasamy Ravi, Claire L. Donohoe, John V. Reynolds, Joanne Lysaght

Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer

  • Open Access
  • Original Article

Ding Jianyi, Gan Haili, Yin Bo, Yang Meiqin, Huang Baoyou, Hu Haoran, Li Fang, Zheng Qingliang, Han Lingfei

Correction to: Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer

  • Open Access
  • Correction

Ding Jianyi, Gan Haili, Yin Bo, Yang Meiqin, Huang Baoyou, Hu Haoran, Li Fang, Zheng Qingliang, Han Lingfei

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

  • Original Article

Renaud Descourt, Laurent Greillier, Maurice Perol, Charles Ricordel, Jean-Bernard Auliac, Lionel Falchero, Radj Gervais, Rémi Veillon, Sabine Vieillot, Florian Guisier, Marie Marcq, Grégoire Justeau, Laurence Bigay-Game, Marie Bernardi, Pierre Fournel, Hélène Doubre, Julian Pinsolle, Karim Amrane, Christos Chouaïd, Chantal Decroisette

Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint

  • Original Article

Jie Lei, Jianfei Zhu, Bengang Hui, Chenghui Jia, Xiaolong Yan, Tao Jiang, Xiaoping Wang

Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer

  • Original Article

Niannian Ji, Meijun Long, Andreu Garcia-Vilanova, Russell Ault, Juan I. Moliva, Kizil A. Yusoof, Neelam Mukherjee, Tyler J. Curiel, Hong Dixon, Jordi B. Torrelles, Robert S. Svatek

Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome

  • Open Access
  • Original Article

Sandra van Wilpe, Shabaz Sultan, Mark A. J. Gorris, Diederik M. Somford, Heidi V. N. Kusters-Vandevelde, Rutger H. T. Koornstra, Winald R. Gerritsen, Michiel Simons, Antoine G. van der Heijden, I. Jolanda M. de Vries, Niven Mehra

Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model

  • Open Access
  • Original Article

Michelle A. Hsu, Stephanie M. Okamura, C. Daniel De Magalhaes Filho, Daniele M. Bergeron, Ahiram Rodriguez, Melissa West, Deepak Yadav, Roger Heim, Jerry J. Fong, Miguel Garcia-Guzman

The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer

  • Original Article

Yohei Nose, Takuro Saito, Kei Yamamoto, Kotaro Yamashita, Koji Tanaka, Kazuyoshi Yamamoto, Tomoki Makino, Tsuyoshi Takahashi, Atsunari Kawashima, Miya Haruna, Michinari Hirata, Azumi Ueyama, Kota Iwahori, Taroh Satoh, Yukinori Kurokawa, Hidetoshi Eguchi, Yuichiro Doki, Hisashi Wada

Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination

  • Original Article

Ryan M. Kahn, Govind Ragupathi, Qin C. Zhou, Alexia Iasonos, Sara Kravetz, Martee L. Hensley, Jason A. Konner, Vicky Makker, William P. Tew, Carol Aghajanian, Paul J. Sabbatini, Roisin E. O’Cearbhaill

TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism

  • Open Access
  • Original Article

Kaikai Zhao, Liyang Jiang, Youjiao Si, Shujie Zhou, Zhaoqin Huang, Xiangjiao Meng

Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis

  • Original Article

Liwei Lv, Yuchen Wu, Han Shi, Xuefei Sun, Zixin Deng, Hongjia Huo, Ruonan Li, Yuanbo Liu

Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis

  • Original Article

Guangyi Jiang, Yu Yang Ng, Johan C. K. Tay, Zhicheng Du, Lin Xiao, Shu Wang, Jianqing Zhu

Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays

  • Original Article

Ning Lou, Cuiling Zheng, Yanrong Wang, Caixia Liang, Qiaoyun Tan, Rongrong Luo, Lei Zhang, Tongji Xie, Yuankai Shi, Xiaohong Han

Hematologic malignancies following immune checkpoint inhibition for solid tumors

  • Open Access
  • Research Report

Mick J. M. van Eijs, Lotte E. van der Wagen, Rogier Mous, Roos J. Leguit, Lisette van de Corput, Anne S. R. van Lindert, Britt B. M. Suelmann, Anna M. Kamphuis, Stefan Nierkens, Karijn P. M. Suijkerbuijk

Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19

  • Research Report

Sara Fioretti, Courtney A. Matson, Kenneth M. Rosenberg, Nevil J. Singh

High salt diet does not impact the development of acute myeloid leukemia in mice

  • Open Access
  • Research Report

Mathangi Janakiraman, Natallia Salei, Gurumoorthy Krishnamoorthy

Neu im Fachgebiet Onkologie

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Weniger aggressive Prostatakrebs-Therapie, gleiche Prognose

Erhalten ältere Prostatakrebs-Patienten vor Therapiebeginn ein geriatrisches Assessment, führt dies häufig zu einer Deeskalation der Behandlung – ohne dass ihre Prognose dadurch schlechter würde. Darauf deuten Erfahrungen aus Frankreich hin. 

Nach kardiovaskulärer Erkrankung steigt das Krebsrisiko

Wer an einer kardiovaskulären Erkrankung (CVD) leidet, hat offenbar ein erhöhtes Risiko, in der Folge auch noch eine Krebsdiagnose zu erhalten. Der Zusammenhang scheint für diverse CVD und Krebsentitäten zu gelten.

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.